These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
298 related articles for article (PubMed ID: 20561044)
1. Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis. Belachew S; Phan-Ba R; Bartholomé E; Delvaux V; Hansen I; Calay P; Hafsi KE; Moonen G; Tshibanda L; Vokaer M Eur J Neurol; 2011 Feb; 18(2):240-245. PubMed ID: 20561044 [TBL] [Abstract][Full Text] [Related]
2. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting. Trojano M; Butzkueven H; Kappos L; Wiendl H; Spelman T; Pellegrini F; Chen Y; Dong Q; Koendgen H; Belachew S; Mult Scler Relat Disord; 2018 Aug; 24():11-19. PubMed ID: 29860197 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries. Putzki N; Yaldizli O; Mäurer M; Cursiefen S; Kuckert S; Klawe C; Maschke M; Tettenborn B; Limmroth V Eur J Neurol; 2010 Jan; 17(1):31-7. PubMed ID: 19614963 [TBL] [Abstract][Full Text] [Related]
4. Natalizumab improves ambulation in relapsing-remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM. Voloshyna N; Havrdová E; Hutchinson M; Nehrych T; You X; Belachew S; Hotermans C; Paes D Eur J Neurol; 2015 Mar; 22(3):570-7. PubMed ID: 25511792 [TBL] [Abstract][Full Text] [Related]
5. Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis. Prosperini L; Giannì C; Barletta V; Mancinelli C; Fubelli F; Borriello G; Pozzilli C J Neurol Sci; 2012 Dec; 323(1-2):104-12. PubMed ID: 23006974 [TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis. Earnshaw SR; Graham J; Oleen-Burkey M; Castelli-Haley J; Johnson K Appl Health Econ Health Policy; 2009; 7(2):91-108. PubMed ID: 19731967 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK. Gani R; Giovannoni G; Bates D; Kemball B; Hughes S; Kerrigan J Pharmacoeconomics; 2008; 26(7):617-27. PubMed ID: 18563952 [TBL] [Abstract][Full Text] [Related]
8. Long-term effects of natalizumab on MRI activity and clinical outcomes in Japanese patients with relapsing-remitting multiple sclerosis. Saida T; Hao Q; Kanda M; Tani Y BMC Neurol; 2023 Aug; 23(1):311. PubMed ID: 37644415 [TBL] [Abstract][Full Text] [Related]
9. Age-corrected neurofilament light chain ratio decreases but does not predict relapse in highly active multiple sclerosis patients initiating natalizumab treatment. Højsgaard Chow H; Petersen ER; Olsson A; Hejgaard Laursen J; Bredahl Hansen M; Oturai AB; Soelberg Sørensen P; Bach Søndergaard H; Sellebjerg F Mult Scler Relat Disord; 2024 Aug; 88():105701. PubMed ID: 38889559 [TBL] [Abstract][Full Text] [Related]
10. Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational study. Baldi E; Guareschi A; Vitetta F; Senesi C; Curti E; Montepietra S; Simone AM; Immovilli P; Caniatti L; Tola MR; Pesci I; Montanari E; Sola P; Granella F; Motti L; Ferraro D Curr Med Res Opin; 2014 Sep; 30(9):1849-55. PubMed ID: 24831186 [TBL] [Abstract][Full Text] [Related]
11. Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis. Ryerson LZ; Foley JF; Defer G; Cohen JA; Arnold DL; Butzkueven H; Cutter G; Giovannoni G; Killestein J; Wiendl H; Sinks S; Kuhelj R; Bodhinathan K; Lasky T Mult Scler Relat Disord; 2023 Apr; 72():104561. PubMed ID: 36931078 [TBL] [Abstract][Full Text] [Related]
12. Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE. Perumal J; Fox RJ; Balabanov R; Balcer LJ; Galetta S; Makh S; Santra S; Hotermans C; Lee L BMC Neurol; 2019 Jun; 19(1):116. PubMed ID: 31176355 [TBL] [Abstract][Full Text] [Related]
13. Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. O'Connor PW; Goodman A; Willmer-Hulme AJ; Libonati MA; Metz L; Murray RS; Sheremata WA; Vollmer TL; Stone LA; Neurology; 2004 Jun; 62(11):2038-43. PubMed ID: 15184611 [TBL] [Abstract][Full Text] [Related]
14. Natalizumab for relapsing remitting multiple sclerosis. Pucci E; Giuliani G; Solari A; Simi S; Minozzi S; Di Pietrantonj C; Galea I Cochrane Database Syst Rev; 2011 Oct; (10):CD007621. PubMed ID: 21975773 [TBL] [Abstract][Full Text] [Related]
15. Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis. Cadavid D; Jurgensen S; Lee S PLoS One; 2013; 8(1):e53297. PubMed ID: 23308186 [TBL] [Abstract][Full Text] [Related]
16. Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study. Gajofatto A; Bianchi MR; Deotto L; Benedetti MD Eur Neurol; 2014; 72(3-4):173-80. PubMed ID: 25226868 [TBL] [Abstract][Full Text] [Related]
17. Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis. Phillips JT; Giovannoni G; Lublin FD; O'Connor PW; Polman CH; Willoughby E; Aschenbach W; Pace A; Hyde R; Munschauer FE Mult Scler; 2011 Aug; 17(8):970-9. PubMed ID: 21421809 [TBL] [Abstract][Full Text] [Related]
18. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. Hutchinson M; Kappos L; Calabresi PA; Confavreux C; Giovannoni G; Galetta SL; Havrdova E; Lublin FD; Miller DH; O'Connor PW; Phillips JT; Polman CH; Radue EW; Rudick RA; Stuart WH; Wajgt A; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA; J Neurol; 2009 Mar; 256(3):405-15. PubMed ID: 19308305 [TBL] [Abstract][Full Text] [Related]
19. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. Kalincik T; Horakova D; Spelman T; Jokubaitis V; Trojano M; Lugaresi A; Izquierdo G; Rozsa C; Grammond P; Alroughani R; Duquette P; Girard M; Pucci E; Lechner-Scott J; Slee M; Fernandez-Bolanos R; Grand'Maison F; Hupperts R; Verheul F; Hodgkinson S; Oreja-Guevara C; Spitaleri D; Barnett M; Terzi M; Bergamaschi R; McCombe P; Sanchez-Menoyo J; Simo M; Csepany T; Rum G; Boz C; Havrdova E; Butzkueven H; Ann Neurol; 2015 Mar; 77(3):425-35. PubMed ID: 25546031 [TBL] [Abstract][Full Text] [Related]
20. Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis. Koch MW; Mostert JP; Wolinsky JS; Lublin FD; Uitdehaag B; Cutter GR Neurology; 2021 Oct; 97(16):e1560-e1570. PubMed ID: 34433679 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]